IDH2 and glioblastoma: Another clinically relevant biomarker is the mutation status of IDH (isocitrate dehydrogenase)1 and IDH2, with approximately 10% of patients with glioblastoma (14) expressing a mutation in either of these genes, which is an early genetic event in gliomagenesis.